Autopsy report · NCT05980598
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
Cause of deathFunding or business
“The Sponsor made the decision to close enrollment as part of a strategic portfolio review.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 6 months before it stopped.
- 27 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Ascendis Pharma A/S
- Sponsor type
- Industry
- Conditions
- Head and Neck Neoplasms
- Interventions
- TransCon TLR7/8 Agonist; Pembrolizumab; TransCon IL-2 β/γ
- Participants
- 27
- Sites
- 65
- Countries
- Georgia, Germany, Hungary, Italy, Poland, Spain, Taiwan, United States
Trials that died the same way
- A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
“Sponsor Decision to close study” - ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
“Sponsor has decided to close study.” - Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
“Sponsor decided to close the study prior to completion of enrollment. This was a business decision and not based on the safety results of the study.” - Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
“Study sponsor decided to close study.” - Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
“Sponsor decision to close study early; not due to safety concerns”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.